475 related articles for article (PubMed ID: 19393853)
1. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
2. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
3. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
5. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
6. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
[TBL] [Abstract][Full Text] [Related]
9. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
Pscherer S; Dietrich ES; Dippel FW; Neilson AR
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
[TBL] [Abstract][Full Text] [Related]
10. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
13. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
14. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
[TBL] [Abstract][Full Text] [Related]
16. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
17. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
[TBL] [Abstract][Full Text] [Related]
18. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
19. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
Xie L; Wei W; Pan C; Du J; Baser O
Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
[TBL] [Abstract][Full Text] [Related]
20. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]